A novel progesterone oral formulation for the treatment of endometrial hyperplasia with reduced adverse signalling compared to synthetic progestins
Background: Natural progesterone is currently unavailable for the treatment of endometrial hyperplasia. The first line of treatment for this condition is with the synthetic progestins Medroxyprogesterone Acetate (MPA) and Levonorgestrel (LNG). However, these hormones frequently trigger side effects...
| Main Author: | |
|---|---|
| Published: |
Swansea University
2015
|
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.752343 |